CompanyADILNasdaqCharlottesville, VA

Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals develops AD04, a small molecule therapeutic for alcohol use disorder in genetically defined patient subpopulations, currently in Phase 3 clinical development.

Stories only

SEC EDGAR ClinicalTrials.gov

8-KSep 18Latest SEC filing, period to Sep 17

Sep 18Latest story

September 2026

Adial holds 2026 annual meeting, adjourns vote on four proposals pending Nasdaq approval

Sep 18PeopleAdial Pharmaceuticals, Inc.

Adial Pharmaceuticals amends PIPE and note exchange agreements ahead of annual meeting

Sep 16PartnershipAdial Pharmaceuticals, Inc.

August 2026

Adial Pharmaceuticals grants inducement stock option to new employee

Aug 25FinancingAdial Pharmaceuticals, Inc.

Adial Pharmaceuticals reports Q2 2026 results, advances AT177 after Azora acquisition

Aug 17Quarterly updateAdial Pharmaceuticals, Inc.

Adial Pharmaceuticals plans CEO and CFO transition tied to 2026 annual meeting vote

Aug 13PeopleAdial Pharmaceuticals, Inc.